Table 2.
Baseline values 2017: mean values and differences of primary outcome variables before (left) and after (right) matching for the control and the treatment group
| Before matching | After matching | |||||
|---|---|---|---|---|---|---|
| Control group | Treatment group | Difference | Control group | Treatment group | Difference | |
| Guideline-adherent care | ||||||
| All four measures fulfilled (0/1) | 0.18 | 0.20 | 0.01 | 0.17 | 0.20 | 0.03 |
| ≥ 2 HbA1c measurements (yearly) (0/1) | 0.81 | 0.81 | 0.00 | 0.80 | 0.81 | 0.01 |
| Lipid profile (yearly) (0/1) | 0.63 | 0.65 | 0.02 | 0.62 | 0.64 | 0.02 |
| Nephropathy status (yearly) or ACE (0/1) | 0.39 | 0.47 | 0.08c | 0.37 | 0.47 | 0.10c |
| Ophthalmologist (every two years) (0/1) | 0.67 | 0.62 | – 0.05a | 0.62 | 0.62 | 0.00 |
| Hospitalization risk | ||||||
| ≥ 1 inpatient hospitalization (0/1) | 0.24 | 0.19 | – 0.04a | 0.19 | 0.19 | 0.01 |
| Health care costs (CHF) | ||||||
| Total | 11,450 | 8783 | – 2667c | 9258 | 8456 | – 802 |
| Outpatient | 8213 | 6814 | – 1400c | 7047 | 6648 | – 400 |
| Inpatient (excl. rehab and nursing homes) | 1823 | 1340 | – 483a | 1323 | 1279 | – 44 |
538 treatment cases in raw data, 530 treatment cases in the matched sample (8 not matched), 5050 control cases. 0/1 Dummy variables, Values indicate shares of patients
ACE Angiotensin-converting enzyme, CHF Swiss Francs
a,b,cStatistically significant difference at 5, 1 and 0.1% level, respectively, based on a t test